Course Report: Design, Conduct and Interpretation of Clinical Trials

October 29-31, 2013
Toulouse, France
 

Olivier Rascol, MD, PhD, Professor of Clinical Pharmacology at Toulouse University Hospital, Toulouse, France; Chair, MDS-European Section
and Joaquim J. Ferreira, MD, PhD, Professor of Neurology at the University of Lisbon, Lisbon, Portugal

FCRINThe Design, Conduct and Interpretation of Clinical Trials in Movement Disorders course was held in Toulouse, France at the University of Toulouse, October 29-31, 2013 under the direction of Prof. Joaquim Ferreira and Prof. Olivier Rascol. The three-day course was jointly organized by the French Clinical Research Infrastructure Network (F-CRIN) and the MDS-European Section. It was also sponsored by the European Huntington's Disease Network (EHDN).

The first day featured an introductory overview on Parkinson's disease and Huntington's disease pathogenesis, clinical phenomenology and management. This first day was especially designed as an initiation dedicated to colleagues from the pharmaceutical industry unfamiliar with movement disorders.

The second day provided participants (coming both from private pharmaceutical industry and academic neurological departments) with an overview on Clinical Trial Methodology with specific reference to Parkinson's disease and Huntington's disease regarding study designs, clinical outcomes, biomarkers, placebo effect, etc.

The third day featured workshops on specific examples of clinical trials in Parkinson's disease and Huntington's disease. Attendees were split into working groups, and each group received a package presenting an imaginary scenario with a documentation summarizing the previous development steps allowing building-up the design of a clinical trial in Parkinson's disease and Huntington's disease. Each scenario was elaborated in advance by the panel, in order to provide illustrative examples of the main types of issues discussed on the previous day.

The specific goal of the course was to improve the efficiency and development of clinical trials in movement disorders. Attended by 29 pharmaceutical industry professionals and academic researchers, the participant feedback was overwhelmingly positive. The MDS-ES is committed to providing additional industry education in the region, and plans for a second, similar course are underway.

For more information contact: MDS Education

Top